Malignant transformation of human benign prostate epithelial cells by high linear energy transfer α-particles

International Journal of Oncology

Volumn 31, Issue 3, 2007, Pages 537-544

  Li, Hongzhen ^a   Gu, Yongpeng ^a   Miki, Jun ^a   Hukku, Bharati ^b   McLeod, David G ^a   Hei, Tom K ^c   Rhim, Johng S ^a  

^a Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^b Cell Culture Characterization Services   (United States)

^c Columbia University ^*  (United States)

Author keywords

Carcinogenesis; Human benign prostate epithelial cells; Immortalization; Malignant transformation; particles

Indexed keywords

ADENOCARCINOMA; ALPHA RADIATION; ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL LINE; CELL TRANSFORMATION; CHROMOSOME ABERRATION; HUMAN; LINEAR ENERGY TRANSFER; MALE; MOUSE; MOUSE MUTANT; PATHOLOGY; PROSTATE; PROSTATE TUMOR; RADIATION INJURY;

ADENOCARCINOMA; ALPHA PARTICLES; ANIMALS; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; HUMANS; LINEAR ENERGY TRANSFER; MALE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASMS, RADIATION-INDUCED; PROSTATE; PROSTATIC NEOPLASMS;

EID: 38449085554     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.3.537     Document Type: Article

References (37)

1. National Research Council Report 1994. Health effects of exposure to radon: time for reassessment. National Academy Press, Washington DC, 1994.
2. Lundin FE, Lloyd JW, Smith EM, Archer VE and Holaday DA: Mortality of uranium miners in relation to radiation exposure, hard-rock mining and cigarette smoking, 1950 through September, 1967. Health Physiol 16: 571-578, 1969.
3. Samet JM and Eradze GM: Radon and lung cancer risk: taking stock at the millennium. Environ Health Perspect 108: 635-641, 2000.
4. US Environmental Protection Agency document EPA 402-K-02-006: A citizen's guide to radon, 2004.
5. Gilbert ES, Cross FT and Dagle GE: Analysis of lung cancer risks in rats exposed to radon. Radiat Res 145: 350-360, 1996.
6. Li Y, Tian Z, Rizvi SM, Bander NH and Allen BJ: In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Prostate Cancer Prostatic Dis 5: 36-46, 2002.
7. McDevitt MR, Barendswaard E, Ma D, Lai L, Curcio MJ, Sgouros G, Ballangrud AM, Yang WH, Finn RD, Pellegrini V, Geerlings MW Jr, Lee M, Brechbiel MW, Bander NH, Cordon-Cardo C and Scheinberg DA: An alpha-particle emitting antibody Bi0213/J591 for radioimmunotherapy of prostate cancer. Cancer Res 60: 6095-6100, 2000.
8. Eatough JP and Henshaw DL: Radon and prostate cancer. Lancet 335: 1292, 1990.
9. Gu Y, Li H, Miki J, Kim KH, Furusato B, Sesterhenn IA, Chu W-S, McLeod DG, Srivastava S, Ewing CM, Isaacs WB and Rhim JS: Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines. Exp Cell Res 312: 831-843, 2006.
10. Hei TK, Piao CQ, Willey JC, Thomas S and Hall EJ: Accelerated paper. Malignant transformation of human bronchial epithelial cells by radon-simulated alpha-particles. Carcinogenesis 15: 431-437, 1994.
11. Zhu LX, Waldren CA, Vannais D and Hei TK: Cellular and molecular analysis of mutagenesis induced by charged particles of defined LET. Radiat Res 145: 251-259, 1996.
12. Roy D, Calaf G and Hei TK: Profiling of differentially expressed genes induced by high LET radiation in breast epithelial cells. Mol Carcinog 31: 192-203, 2001. (Pubitemid 32831345)
13. Hukku B and Rhim JS: Role of chromosome #5 in immortalization and tumorigenesis of human keratinocytes. Cancer Genet Cytogenet 68: 22-31, 1993.
14. Schröck E, Du Manoir S, Veldman T, et al: Multicolor spectral karyotyping of human chromosomes. Science 273: 494-497, 1996.
15. Speicher MR, Gwyn Ballard S and Ward DC: Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nat Genet 12: 368-375, 1996. (Pubitemid 26105926)
16. Lochter A, Galosy S, Muschler J, Freedman N, Werb Z and Bissell MJ: Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelialto-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol 139: 1861-1872, 1997.
17. Savelieva E, Belair CD, Newton MA, et al: 20q gain associated with immortalization: 20q13.2 amplification correlates with genomic instability in human papillomavirus 16 transformed human uroepithelial cells. Oncogene 14: 551-560, 1997.
18. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, Ewing CM, Platz EA, Ferdinandusse S, Wanders RJ, Trent JM, Isaacs WB and De Marzo AM: Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 62: 2220-2226, 2002.
19. Wilson SR, Gallagher S, Warpeha K and Hawthorne SJ: Amplification of MMP-2 and MMP-9 production by prostate cancer cell lines via activation of protease-activation receptors. Prostate 60: 168-174, 2004. (Pubitemid 38758582)
20. Dong Z, Bonfil RD, Chinni S, Deng X, Trindade Filho JC, Bernardo M, Vaishampayan U, Che M, Sloane BF, Sheng S, Fridman R and Cher ML: Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. Am J Pathol 166: 1173-1186, 2005.
21. Morgia G, Falsaperla M, Malaponte G, Madonia M, Indelicato M, Travali S and Mazzarino MC: Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res 33: 44-50, 2005.
22. Hall EJ and Hei TK: Genomic instability and bystander effects induced by high-LET radiation (review). Oncogene 22: 7034-7042, 2003.
23. Brothman AR: Cytogenetics and molecular genetics of cancer of the prostate (review). Am J Med Genet 115: 150-156, 2002.
24. Das K, Lau W, Sivaswaren C, Ph T, Foot-Chong S, Si T and Cheng C: Chromosomal changes in prostate cancer: a fluorescence in situ hybridization study. Clin Genet 1: 40-47, 2005.
25. Kasahara K, Taguchi T, Yamasaki I, Kamada M and Shuin T: Genetic changes in localized prostate cancer of Japanese patients shown by comparative genomic hybridization. Cancer Genet Cytogenet 159: 84-88, 2005. (Pubitemid 40626723)
26. Phillips JL, Hayward SW, Wang Y, Vasselli J, Pavlovich C, Padilla-Nash H, Pezullo JR, Ghadimi BM, Grossfeld GD, Rivera A, Linehan WM, Cunha GR and Ried T: The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis. Cancer Res 61: 8143-8149, 2001.
27. Rokman A, Baffoe-Bonnie AB, Gillanders E, Fredriksson H, Autio V, Ikonen T, Gibbs KD, Jones M, Gildea D, Freas-Lutz D, Markey C, Matikainen MP, Koivisto PA, Tammela TL, Kallioniemi OP, Trent J, Bailey-Wilson JE and Schleutker J: Hereditary prostate cancer in Finland: fine-mapping validates 3p26 as a major predisposition locus. Hum Genet 116: 43-50, 2005.
28. Slager SL, Zarfas KE, Brown WM, Lange EM, McDonnell SK, Wojno KJ and Cooney KA: Genome-wide linkage scan for prostate cancer aggressiveness loci using families from the University of Michigan Prostate Cancer Genetics Project. Prostate 66: 173-179, 2006.
29. Verhagen PC, Hermans KG, Brok MO, van Weerden WM, Tilanus MG, De Weger RA, Boon TA and Trapman J: Deletion of chromosomal region 6q14-16 in prostate cancer. Int J Cancer 102: 142-147, 2002.
30. Visakorpi T: Molecular genetics of prostate cancer. Ann Chir Gynaecol 88: 11-16, 1999.
31. Xu J, Dimitrov L, Chang BL, Adams TS, Turner AR, Meyers DA, Eeles RA, Easton DF, Foulkes WD, Simard J, Giles GG, Hopper JL, Mahle L, Moller P, Bishop T, Evans C, Edwards S, Meitz J, Bullock S, Hope Q, Hsieh CL, Halpern J, Balise RN, Oakley-Girvan I, Whittemore AS, Ewing CM, Gielzak M, Isaacs SD, Walsh PC, Wiley KE, Isaacs WB, Thibodeau SN, McDonnell SK, Cunningham JM, Zarfas KE, Hebbring S, Schaid DJ, Friedrichsen DM, Deutsch K, Kolb S, Badzioch M, Jarvik GP, Janer M, Hood L, Ostrander EA, Stanford JL, Lange EM, Beebe-Dimmer JL, Mohai CE, Cooney KA, Ikonen T, Baffoe-Bonnie A, Fredriksson H, Matikainen MP, Tammela TLJ, Bailey-Wilson J, Schleutker J, Maier C, Herkommer K, Hoegel JJ, Vogel W, Paiss T, Wiklund F, Emanuelsson M, Stenman E, Jonsson BA, Gronberg H, Camp NJ, Farnham J, Cannon-Albright LA and Seminara D: The ACTANE Consortium. A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet 77: 219-229, 2005.
32. Levine AJ, Momand J and Finlay CA: The p53 tumor suppressor gene. Nature 351: 453-456, 1991.
33. Weinberg RA: Tumor suppressor genes. Science 254: 1138-1146, 1991.
34. Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI and Isaacs WB: Allelic loss of chromosomes 16q and 101 in human prostate cancer. Proc Natl Acad Sci USA 87: 8751-8755, 1990. (Pubitemid 120007586)
35. Isaacs WB, Carter BS and Ewing CM: Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51: 4716-4720, 1991.
36. Wazer DE, Chu Q, Liu XL, Gao Q, Safaii H and Band V: Loss of p53 protein during radiation transformation of primary human mammary epithelial cells. Mol Cell Biol 14: 2468-2478, 1994.
37. Piao CQ, Willey JC and Hei TK: Alterations of p53 in tumorigenic human bronchial epithelial cells correlate with metastatic potential. Carcinogenesis 20: 1529-1533, 1999.